Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1983 May;23(5):637–640. doi: 10.1128/aac.23.5.637

Susceptibility of recent clinical isolates of herpes simplex virus to 5-ethyl-2'-deoxyuridine: preferential inhibition of herpes simplex virus type 2.

C Z Teh, S L Sacks
PMCID: PMC184779  PMID: 6307130

Abstract

We examined the in vitro susceptibilities of three reference strains and 41 recent clinical isolates of herpes simplex virus types 1 and 2 to 5-ethyl-2'-deoxyuridine. This thymidine analog exerts a type 2-preferential but not a type 2-specific antiviral effect. Utilizing a microtiter assay with BHK-21 cells, we found that the mean (+/- standard deviation) 50% inhibitory dose for herpes simplex virus type 1 isolates was 0.58 +/- 0.30 micrograms/ml as compared with 0.33 +/- 0.20 microgram/ml for herpes simplex virus type 2 isolates. Isolates were typed according to their susceptibilities to (E)-5-(2-bromovinyl)-2'-deoxyuridine and by an indirect fluorescent-antibody technique in which monoclonal antibody combinations were used. A cytotoxicity assay in which the incorporation of [1',2'-3H]deoxyuridine was measured revealed a 50% inhibitory dose of 37.5 micrograms/ml, suggesting a favorable therapeutic index for this compound.

Full text

PDF
637

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allaudeen H. S., Kozarich J. W., Bertino J. R., De Clercq E. On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine. Proc Natl Acad Sci U S A. 1981 May;78(5):2698–2702. doi: 10.1073/pnas.78.5.2698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cheng Y. C. A rational approach to the development of antiviral chemotherapy: alternative substrates of herpes simplex virus Type 1 (HSV-1) and Type 2 (HSV-2) thymidine kinase (TK). Ann N Y Acad Sci. 1977 Mar 4;284:594–598. doi: 10.1111/j.1749-6632.1977.tb21992.x. [DOI] [PubMed] [Google Scholar]
  3. De Clercq E. Comparative efficacy of antiherpes drugs in different cell lines. Antimicrob Agents Chemother. 1982 Apr;21(4):661–663. doi: 10.1128/aac.21.4.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis. 1980 May;141(5):563–574. doi: 10.1093/infdis/141.5.563. [DOI] [PubMed] [Google Scholar]
  5. Descamps J., De Clercq E. Specific phosphorylation of E-5-(2-iodovinyl)-2'-deoxyuridine by herpes simplex virus-infected cells. J Biol Chem. 1981 Jun 25;256(12):5973–5976. [PubMed] [Google Scholar]
  6. Elze K. L. Ten years of clinical experiences with ethyldeoxyuridine. Adv Ophthalmol. 1979;38:134–139. [PubMed] [Google Scholar]
  7. Luby J. Therapy in genital herpes. N Engl J Med. 1982 Jun 3;306(22):1356–1357. doi: 10.1056/NEJM198206033062209. [DOI] [PubMed] [Google Scholar]
  8. Mayo D. R. Differentiation of herpes simplex virus types 1 and 2 by sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine. J Clin Microbiol. 1982 Apr;15(4):733–736. doi: 10.1128/jcm.15.4.733-736.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. McLaren C., Sibrack C. D., Barry D. W. Spectrum of sensitivity of acyclovir of herpes simplex virus clinical isolates. Am J Med. 1982 Jul 20;73(1A):376–379. doi: 10.1016/0002-9343(82)90126-7. [DOI] [PubMed] [Google Scholar]
  10. Merigan T. C., Gregory D. F., Petralli J. K. Physical properties of human interferon prepared in vitro and in vivo. Virology. 1966 Aug;29(4):515–522. doi: 10.1016/0042-6822(66)90276-5. [DOI] [PubMed] [Google Scholar]
  11. Parris D. S., Harrington J. E. Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates. Antimicrob Agents Chemother. 1982 Jul;22(1):71–77. doi: 10.1128/aac.22.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pereira L., Dondero D. V., Gallo D., Devlin V., Woodie J. D. Serological analysis of herpes simplex virus types 1 and 2 with monoclonal antibodies. Infect Immun. 1982 Jan;35(1):363–367. doi: 10.1128/iai.35.1.363-367.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Schaeffer H. J., Beauchamp L., de Miranda P., Elion G. B., Bauer D. J., Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature. 1978 Apr 13;272(5654):583–585. doi: 10.1038/272583a0. [DOI] [PubMed] [Google Scholar]
  14. Wohlrab F., Francke B. Deoxyribopyrimidine triphosphatase activity specific for cells infected with herpes simplex virus type 1. Proc Natl Acad Sci U S A. 1980 Apr;77(4):1872–1876. doi: 10.1073/pnas.77.4.1872. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES